Clinical investigation of tazobactam/piperacillin in urology

• Published in: CHEMOTHERAPY Vol. 42; no. Supplement2; pp. 765 - 769
• Main Authors: Masuda, Aiichiro, Watanabe, Satoshi, Usui, Yukio, Ishida, Toshiya, Arihara, Kazuo, Tanaka, Motoaki, Nakajima, Noboru, Hoshino, Hideaki, Nishizawa, Kazuaki, Shiramizu, Miki, Nagata, Yoshihiro, Katsuoka, Yoji, Kinoshita, Hidechika, Kawamura, Nobuo, Okada, Keishi, Inatsuchi, Hiroaki, Matsushita, Kazuo, Tanikawa, Katsumi, Ohkoshi, Masaaki
• Format: Journal Article
• Language: Japanese
• Published: Japanese Society of Chemotherapy 1994
• Subjects: tazobactam/piperacillin
• ISSN: 0009-3165; 1884-5894
• DOI: 10.11250/chemotherapy1953.42.Supplement2_765

We clinically investigated tazobactam/piperacillin (TAZ/PIPC), a newly developed injectable antibiotic, in 4 patients with acute uncomplicated pyelonephritis and in 11 patients with chronic complicated urinary tract infection. TAZ/PIPC was given at 1.25 or 2.5g b. i. d. for several days to 15 patients with urinary tract infection. Three patients with acute uncomplicated pyelonephritis and 7 patients with chronic complicated UTI were evaluated by the criteria of the UTI Commitee. In acute uncomplicated pyelonephritis, clinical efficacy was excellent in 1 and moderate in 2 out of 3 patients evaluated by the criteria of the UTI Committee. According to doctor's evaluation, clinical efficacy was excellent in 3 patients and good in 1. In chronic complicated UTI, clinical efficacy was moderate in 4 and poor in 3 out of 7 patients evaluated by the criteria of the UTI Commitee. According to doctor's evaluation, clinical efficacy was excellent in 1 patient, good in 9 and unknown in 1, the overall rate being 100%. Bacteriologically, all strains isolated from acute uncomplicated pyelonephritis were eradicated after TAZ/PIPC treatment. In chronic complicated UTI, 12 of 14 strains (85.7%) were eradicated after TAZ/PIPC treatment. Neither subjective adverse reactions nor abnormal laboratory findings related to the drug were observed.